Key result
Endovascular therapy, bypass, and chemotherapy fail to halt iliac artery intimal sarcoma progression at 20 months.
Case Report (n=1)
Intimal sarcoma of the iliac artery is a rare and aggressive tumor that can present as artery occlusion and may be resistant to standard therapies like stenting and chemotherapy.
Emphasizes treatment resistance in rare iliac intimal sarcoma; leaves open need for novel therapies in this aggressive entity.
We present a rare case of intimal sarcoma arising from the common iliac artery in an 82-year-old man who presented with intermittent claudication. He had undergone endovascular therapy with self-expanding stents to both iliac arteries that had occluded soon after placement. After salvage bypass grafting, a diagnosis of intimal sarcoma with angiosarcoma phenotype from the iliac artery was made. Further bypass graft surgery relieved symptoms temporarily. However, the tumor progressed and the left limb became ischemic. The chemotherapy of eribulin did not prevent tumor progression. The patient died of the disease 20 months after the first surgery. J. Med. Invest. 66 : 205-208, February, 2019.
No takes yet. Share an insight, caveat, or question.
Kano et al. (2019) conducted a case report in Intimal sarcoma arising from the common iliac artery (n=1). Endovascular therapy, bypass grafting, and eribulin chemotherapy was evaluated on Tumor progression and survival. In an 82-year-old man, intimal sarcoma of the common iliac artery progressed despite endovascular therapy, bypass grafting, and eribulin chemotherapy, leading to death at 20 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: